Tesamorelin: An Approved Molecule With a Narrow Indication

The short version

Tesamorelin is a synthetic peptide modeled on human growth hormone-releasing hormone (GHRH). Its job is to make the pituitary gland secrete more of your own growth hormone (GH) in pulses — not to replace GH, but to amplify what the body already produces. More GH drives up IGF-1, and the combination preferentially mobilizes fat from visceral depots around the abdomen.

The FDA approved tesamorelin in 2010 for a specific condition: excess abdominal fat in HIV-infected adults experiencing lipodystrophy from antiretroviral therapy. Every well-controlled human trial this desk cites was conducted in that population. A 2026 pooled analysis of five RCTs in HIV-associated lipodystrophy quantified a mean visceral fat reduction of 27.7 cm2 alongside reductions in trunk fat and hepatic fat fraction ^[1]. For anyone outside that indication — general visceral-fat reduction, anti-aging, non-HIV fatty liver — evidence is mechanistically plausible but not established by large RCTs. This page reports what was studied. It does not advise on use or list any human dose.

What it is

Tesamorelin acetate is a 44-amino-acid synthetic analogue of human GHRH(1-44)-NH2, the natural hormone that signals the pituitary to release GH. The key modification is a trans-3-hexenoic acid group conjugated to the N-terminus, which blocks cleavage by dipeptidyl peptidase-IV (DPP-IV) and extends plasma stability well beyond native GHRH. The result is a GHRH molecule that survives in circulation long enough to reach and stimulate pituitary somatotroph cells at meaningful levels.

It is supplied as the acetate salt. You will also see it referenced by its development code TH9507 and by descriptions such as Trans-3-hexenoyl-GHRH(1-44) amide or growth hormone-releasing factor analogue. It is a prescription drug in its approved indication; outside that indication, research-grade tesamorelin is supplied for laboratory research and is not approved for general human self-administration.

How it works

Tesamorelin binds the GHRH receptor (GHRH-R) on anterior-pituitary somatotroph cells and activates the Gs/adenylyl-cyclase/cAMP/PKA cascade, stimulating synthesis and pulsatile secretion of endogenous GH. That GH signal drives the liver to produce IGF-1, and together GH and IGF-1 promote lipolysis — the breakdown of stored fat — with a preferential effect on visceral adipose tissue rather than subcutaneous fat.

Because tesamorelin amplifies the body's own GH rhythm rather than delivering exogenous GH, its metabolic profile differs from recombinant GH therapy. In 13 healthy men given tesamorelin for two weeks, mean overnight GH rose by 0.5 µg/L (P=0.004) and IGF-1 by 181 µg/L (P<0.0001), while fasting glucose and insulin-stimulated glucose uptake were not significantly affected — confirming the mechanism operates through the native GH axis without disrupting insulin sensitivity at short durations ^[4]. The GH-axis stimulation also raises serum IGF-1, a growth factor; while pivotal trials showed no excess malignancy signal over 52 weeks, active malignancy is a labeled contraindication and long-term oncologic-safety data are limited.

What the research shows

Pooled efficacy (2026 meta-analysis). The most comprehensive quantification of tesamorelin's effects comes from a 2026 meta-analysis of five RCTs in HIV-associated lipodystrophy. Mean visceral adipose tissue reduction was 27.71 cm2 (95% CI: -38.37 to -17.06; P<0.001), trunk fat fell by 1.18 kg, hepatic fat fraction dropped by 4.28%, and lean body mass increased by 1.42 kg — all statistically significant with no serious adverse events reported across the pooled sample ^[1].

JAMA RCT (6 months, n=50). In a 2014 JAMA trial of 50 antiretroviral-treated HIV adults, tesamorelin produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) at six months ^[3]. This is the most precise single-trial hepatic-fat estimate in the corpus.

52-week sustained reduction (n=273 vs 137 placebo). The 52-week program demonstrated sustained visceral fat reduction of -18% relative to baseline (P<0.001 vs baseline) held across the full year. Importantly, visceral fat reaccumulated upon discontinuation, and glucose parameters over 52 weeks were not clinically significant ^[5].

Pivotal Phase 3 (n=412). The original Phase 3 RCT in 412 HIV patients found VAT -15.2% in the tesamorelin arm versus +5.0% in placebo; triglycerides fell by 50 mg/dL (versus +9 mg/dL placebo) and IGF-1 increased by 81.0% ^[6]. This trial formed the basis for FDA approval.

GH axis and glucose. In 13 healthy men, two weeks of tesamorelin significantly elevated GH and IGF-1 without affecting fasting glucose or insulin-stimulated glucose uptake ^[4], though the 52-week data flag that modest glucose perturbation can occur with longer exposure and warrants monitoring in individuals with prediabetes.

Safety context. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E — unlikely cause of clinically apparent liver injury — with no attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[2]. A 2026 structured sports-medicine review classifies it among GHRH analogues with uncertain safety profiles and widespread antidoping restrictions ^[7].

Reported effects, cautions & safety

Tesamorelin's human safety profile is well characterized within its approved indication. Several cautions define the limits of that profile:

• Approved only for HIV-associated lipodystrophy. The FDA indication is narrow: excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. General visceral-fat reduction, non-HIV NAFLD, anti-aging, and cognitive applications are off-label and investigational ^[2].
• Trial generalizability. All pivotal trials enrolled HIV-positive adults on antiretroviral therapy. Generalizability to non-HIV populations is mechanistically plausible but not validated by large RCTs ^[1].
• Reaccumulation on discontinuation. Visceral fat reaccumulated within weeks of stopping treatment in the 52-week trial ^[5]. Benefits depend on continued dosing.
• IGF-1 elevation and oncology caution. GH-axis stimulation raises IGF-1; active malignancy is a labeled contraindication and long-term oncologic-safety data beyond 52 weeks are limited ^[2].
• Glucose monitoring. Modest glucose perturbation can occur; monitoring is warranted in individuals with prediabetes or dysglycemia, though dedicated T2D trials found no significant HbA1c change ^[5].
• WADA prohibition. Tesamorelin is prohibited in sport under the WADA Prohibited List S2 category (peptide hormones, growth factors, related substances and mimetics) as a GHRH analogue, in- and out-of-competition ^[7].
• Research-grade supply. Research-grade material sold for laboratory use lacks the purity, potency oversight, and sterility assurance of the pharmaceutical product.

Where it fits in metabolic research

Tesamorelin occupies a specific and well-defined niche: the only GHRH analogue with FDA approval, backed by multiple RCTs, but with that approval bounded tightly to one indication in one population. Its VAT reduction data are some of the most precisely measured in the metabolic peptide literature — effect sizes, confidence intervals, 52-week sustainability all quantified ^[1][5][6]. What it is not is a general weight-loss tool; the head-to-head contrast with retatrutide, which drives broader bodyweight reduction via a completely different receptor set, makes that distinction concrete. See the comparison page for how the two line up.